Verified Nov 2026
Other
·
San Gwann
·
Since 2020
Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.
Adalvo at a glance
Revenue
$100-250M
Est. band
Employees
200-500
Founded
2020
Headquarters
San Gwann
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.
At a glance
Attribute | Detail |
|---|---|
Founded | 2020 |
Headquarters | San Gwann |
Employees | 200-500 |
Revenue | $100-250M (estimated) |
What Adalvo makes
The company manufactures generic pharmaceuticals, peptides, and biosimilar products including Azelastine/Fluticasone nasal spray and Cladribine tablets, with a focus on regulatory approval and commercialization services.
Latest developments
2026-11-09 — Adalvo confirms launch of semaglutide in Brazil - Adalvo (adalvo.com)
2026-10-27 — Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar programme from Enzene | Enzene (enzene.com)
2026-10-21 — Strengthening Adalvo’s leadership in the GLP-1 space | Adalvo (linkedin.com)
2026-08-31 — Libbs e Adalvo fecham novo acordo exclusivo para trazer tratamento de Sistema Nervoso Central ao Brasil - Portal Revista Kdea 360 (revistakdea360.com.br)
2026-07-21 — Adalvo: Anil Okay baut globale Pharma-Plattform aus - forbes.swiss (forbes.swiss)
2026-05-21 — Adalvo is pleased to announce the signing of two new strategic distribution partnerships with Blanver, a prominent Brazilian pharmaceutical company, for two technically differentiated, value-added oncology products. | Adalvo (linkedin.com)
Company details
Adalvo operates as a private company with partnerships spanning over 140 countries, serving large pharmaceutical manufacturers and commercial partners across multiple therapeutic areas. Adalvo was founded in 2020, has an estimated 200-500 employees, and is headquartered in San Gwann.
Frequently asked questions
What does Adalvo do?
Adalvo is a Malta-based pharmaceutical company founded in 2020 with 200–500 employees and estimated revenue of $100–250 million. It develops and commercializes generic pharmaceuticals, peptides, and biosimilar products for oncology, women's health, cardiovascular, CNS, and rare-disease markets. The company operates through an asset-light model and has over 170 commercial partnerships across 140 countries. Recent activity includes a semaglutide launch in Brazil and expansion of its biosimilars portfolio.
Where is Adalvo headquartered?
Adalvo is headquartered in San Gwann.
When was Adalvo founded?
Adalvo was founded in 2020.
How big is Adalvo?
Adalvo has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
